Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 36.51%
March 31, 2026 -34.10%
December 31, 2025 -514.9%
September 30, 2025 -5.01K%
June 30, 2025 -3.11K%
March 31, 2025 -4.04K%
December 31, 2024 -1.66K%
September 30, 2024 -2.52K%
June 30, 2024 -8.20K%
March 31, 2024 -2.23K%
December 31, 2023 -2.69K%
September 30, 2023 -1.44K%
June 30, 2023 -1.15K%
March 31, 2023 -1.23K%
December 31, 2022 -1.26K%
September 30, 2022 -45.71%
June 30, 2022 -895.2%
March 31, 2022 -433.5%
December 31, 2021 -724.7%
September 30, 2021 -789.6%
June 30, 2021 -811.0%
March 31, 2021 -89.12%
December 31, 2020 -5.01%
September 30, 2020 -116.8%
June 30, 2020 -51.63%
Date Value
March 31, 2020 -69.86%
December 31, 2019 -212.2%
September 30, 2019 -268.1%
June 30, 2019 -98.38%
March 31, 2019 -234.2%
December 31, 2018 -666.6%
September 30, 2018 -181.0%
June 30, 2018 -147.6%
March 31, 2018 -98.61%
December 31, 2017 -44.07%
September 30, 2017 -88.74%
June 30, 2017 -36.12%
March 31, 2017 -60.24%
December 31, 2016 -97.63%
September 30, 2016 -61.27%
June 30, 2016 -95.30%
March 31, 2016 -150.4%
December 31, 2015 -80.18%
September 30, 2015 -73.13%
June 30, 2015 -92.43%
March 31, 2015 76.23%
December 31, 2014 57.67%
September 30, 2014 -254.1%
June 30, 2014 -449.1%
March 31, 2014 41.37%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Repligen Corp. 2.45%
AC Immune SA 12.40%
Amgen, Inc. 23.59%
Geron Corp. -29.02%
Neurocrine Biosciences, Inc. 15.06%